Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090911575> ?p ?o ?g. }
- W2090911575 endingPage "1384" @default.
- W2090911575 startingPage "1378" @default.
- W2090911575 abstract "Background & AimsCrohn's disease (CD) is associated with altered bone metabolism. This study examined changes in bone formation and resorption after infliximab induction and associations between bone biomarkers, linear growth, and disease activity (Pediatric Crohn's Disease Activity Index [PCDAI]) after 54 weeks of infliximab therapy.MethodsOne hundred twelve subjects ages 6–17 years with moderate to severe CD received infliximab induction (5 mg/kg/dose) at weeks 0, 2, and 6; week-10 responders were randomized to infliximab every 8 or every 12 weeks maintenance therapy. Serum bone-specific alkaline phosphatase (BSAP), N-terminal propeptide of type 1 collagen (P1NP), urine C-telopeptide of collagen cross-links (CTX-1), and deoxypyrodinoline (DPD) were collected at baseline and 10 weeks. PCDAI and height z-scores were assessed at baseline and at 10 and 54 weeks.ResultsModels were adjusted for bone age, gender, height, and steroid use. Baseline BSAP and P1NP levels were negatively associated with PCDAI (both P = .01). BSAP and P1NP increased during induction (both P < .001) and were associated with 54-week increases in height z-score (P < .05 and P < .001, respectively). Improvements in P1NP were associated with 54-week decreases in PCDAI (P = .01). CTX-1 and DPD also increased during induction (P < .001 and P = .01, respectively) but were not associated with changes in PCDAI. Changes in CTX-1 were associated with improvements in height z-score (P < .002).ConclusionsInfliximab therapy is associated with dramatic increases in BSAP and P1NP, consistent with inhibition of tumor necrosis factor–α effects on osteoblasts. The increases in CTX-1 and DPD likely reflect coupling of bone formation and resorption and increases in linear growth. Crohn's disease (CD) is associated with altered bone metabolism. This study examined changes in bone formation and resorption after infliximab induction and associations between bone biomarkers, linear growth, and disease activity (Pediatric Crohn's Disease Activity Index [PCDAI]) after 54 weeks of infliximab therapy. One hundred twelve subjects ages 6–17 years with moderate to severe CD received infliximab induction (5 mg/kg/dose) at weeks 0, 2, and 6; week-10 responders were randomized to infliximab every 8 or every 12 weeks maintenance therapy. Serum bone-specific alkaline phosphatase (BSAP), N-terminal propeptide of type 1 collagen (P1NP), urine C-telopeptide of collagen cross-links (CTX-1), and deoxypyrodinoline (DPD) were collected at baseline and 10 weeks. PCDAI and height z-scores were assessed at baseline and at 10 and 54 weeks. Models were adjusted for bone age, gender, height, and steroid use. Baseline BSAP and P1NP levels were negatively associated with PCDAI (both P = .01). BSAP and P1NP increased during induction (both P < .001) and were associated with 54-week increases in height z-score (P < .05 and P < .001, respectively). Improvements in P1NP were associated with 54-week decreases in PCDAI (P = .01). CTX-1 and DPD also increased during induction (P < .001 and P = .01, respectively) but were not associated with changes in PCDAI. Changes in CTX-1 were associated with improvements in height z-score (P < .002). Infliximab therapy is associated with dramatic increases in BSAP and P1NP, consistent with inhibition of tumor necrosis factor–α effects on osteoblasts. The increases in CTX-1 and DPD likely reflect coupling of bone formation and resorption and increases in linear growth." @default.
- W2090911575 created "2016-06-24" @default.
- W2090911575 creator A5006726610 @default.
- W2090911575 creator A5006797062 @default.
- W2090911575 creator A5019018783 @default.
- W2090911575 creator A5023154420 @default.
- W2090911575 creator A5025200316 @default.
- W2090911575 creator A5034407359 @default.
- W2090911575 creator A5045032363 @default.
- W2090911575 creator A5045988031 @default.
- W2090911575 creator A5052046238 @default.
- W2090911575 creator A5054537181 @default.
- W2090911575 creator A5060357056 @default.
- W2090911575 creator A5067402350 @default.
- W2090911575 creator A5086034125 @default.
- W2090911575 date "2008-12-01" @default.
- W2090911575 modified "2023-10-04" @default.
- W2090911575 title "Improvement in Biomarkers of Bone Formation During Infliximab Therapy in Pediatric Crohn's Disease: Results of the REACH Study" @default.
- W2090911575 cites W1963577696 @default.
- W2090911575 cites W1964151845 @default.
- W2090911575 cites W1966440512 @default.
- W2090911575 cites W1971855336 @default.
- W2090911575 cites W1976517293 @default.
- W2090911575 cites W1982326982 @default.
- W2090911575 cites W1987767675 @default.
- W2090911575 cites W1995178297 @default.
- W2090911575 cites W2006849448 @default.
- W2090911575 cites W2007684928 @default.
- W2090911575 cites W2020181500 @default.
- W2090911575 cites W2029791051 @default.
- W2090911575 cites W2034528005 @default.
- W2090911575 cites W2036576846 @default.
- W2090911575 cites W2037426631 @default.
- W2090911575 cites W2039896177 @default.
- W2090911575 cites W2043780895 @default.
- W2090911575 cites W2046116619 @default.
- W2090911575 cites W2049663776 @default.
- W2090911575 cites W2061279920 @default.
- W2090911575 cites W2064699495 @default.
- W2090911575 cites W2066521125 @default.
- W2090911575 cites W2069487594 @default.
- W2090911575 cites W2076277955 @default.
- W2090911575 cites W2085627522 @default.
- W2090911575 cites W2090685459 @default.
- W2090911575 cites W2091656394 @default.
- W2090911575 cites W2092004067 @default.
- W2090911575 cites W2099527909 @default.
- W2090911575 cites W2116847662 @default.
- W2090911575 cites W2121444149 @default.
- W2090911575 cites W2133275957 @default.
- W2090911575 cites W2134900917 @default.
- W2090911575 cites W2171341132 @default.
- W2090911575 cites W4233503238 @default.
- W2090911575 cites W4236902433 @default.
- W2090911575 cites W4241323920 @default.
- W2090911575 cites W4243859586 @default.
- W2090911575 doi "https://doi.org/10.1016/j.cgh.2008.07.010" @default.
- W2090911575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19081527" @default.
- W2090911575 hasPublicationYear "2008" @default.
- W2090911575 type Work @default.
- W2090911575 sameAs 2090911575 @default.
- W2090911575 citedByCount "102" @default.
- W2090911575 countsByYear W20909115752012 @default.
- W2090911575 countsByYear W20909115752013 @default.
- W2090911575 countsByYear W20909115752014 @default.
- W2090911575 countsByYear W20909115752015 @default.
- W2090911575 countsByYear W20909115752016 @default.
- W2090911575 countsByYear W20909115752017 @default.
- W2090911575 countsByYear W20909115752018 @default.
- W2090911575 countsByYear W20909115752019 @default.
- W2090911575 countsByYear W20909115752020 @default.
- W2090911575 countsByYear W20909115752021 @default.
- W2090911575 countsByYear W20909115752022 @default.
- W2090911575 countsByYear W20909115752023 @default.
- W2090911575 crossrefType "journal-article" @default.
- W2090911575 hasAuthorship W2090911575A5006726610 @default.
- W2090911575 hasAuthorship W2090911575A5006797062 @default.
- W2090911575 hasAuthorship W2090911575A5019018783 @default.
- W2090911575 hasAuthorship W2090911575A5023154420 @default.
- W2090911575 hasAuthorship W2090911575A5025200316 @default.
- W2090911575 hasAuthorship W2090911575A5034407359 @default.
- W2090911575 hasAuthorship W2090911575A5045032363 @default.
- W2090911575 hasAuthorship W2090911575A5045988031 @default.
- W2090911575 hasAuthorship W2090911575A5052046238 @default.
- W2090911575 hasAuthorship W2090911575A5054537181 @default.
- W2090911575 hasAuthorship W2090911575A5060357056 @default.
- W2090911575 hasAuthorship W2090911575A5067402350 @default.
- W2090911575 hasAuthorship W2090911575A5086034125 @default.
- W2090911575 hasConcept C125870589 @default.
- W2090911575 hasConcept C126322002 @default.
- W2090911575 hasConcept C131075544 @default.
- W2090911575 hasConcept C134018914 @default.
- W2090911575 hasConcept C160160445 @default.
- W2090911575 hasConcept C170033053 @default.
- W2090911575 hasConcept C181199279 @default.
- W2090911575 hasConcept C185592680 @default.
- W2090911575 hasConcept C2777138892 @default.
- W2090911575 hasConcept C2779134260 @default.